Overview

Clinical Trial Nuedexta in Subjects With ALS

Status:
Completed
Trial end date:
2015-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether Nuedexta is effective in the treatment of symptoms (impaired speech, swallowing, and saliva control)associated with Amyotrophic Lateral Sclerosis (ALS).
Phase:
Phase 2
Details
Lead Sponsor:
Center for Neurologic Study, La Jolla, California,
Collaborators:
ALS Association
State University of New York - Upstate Medical University
Treatments:
Dextromethorphan
Quinidine